Trial Profile
Bevacizumab in combination with first-line metastatic chemotherapy for advanced NSCLC (aNSCLC), with Brain Metastasis, a French Cohort Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer